-
11 2021-03
NEURELIS ANNOUNCES CLOSE OF $114 MILLION SERIES D FINANCING ROUND TO ADVANCE NEUROSCIENCE FOCUS
· 2021 financing will be a catalyst to further establish Neurelis as a best-in-class epilepsy company
· Funds will enhance growth and commercial penetration of company’s lead orphan drug product, VALTOCO? (diazepam nasal spray), and support pipeline development and expansion
· Company also announces appointment of healthcare industry expert Alexander Kwit to its Board of Directors
-
08 2021-03
Wugen宣布與晨泰醫藥在亞洲達成獨家合作協議 以細胞療法治療癌癥
Wugen Inc 是一家臨床階段生物科技公司，正在研發新穎的通用型自然殺傷(NK)和T細胞療法治療癌癥，今天宣布已經與晨泰醫藥公司進入獨家許可和合作協議，以在亞洲生產、開發、和商業化其同種異體細胞產品。
-
04 2021-02
國產首款球囊擴張式主動脈瓣膜Prizvalve?正式進入注冊臨床研究
2021年1月，紐脈醫療自主研發的Prizvalve?經導管主動脈瓣膜系統（以下簡稱“Prizvalve?系統”）順利通過科技部遺傳辦備案（備案號：2021BAL0040）審批，正式開始進入注冊臨床研究階段。Prizvalve?系統全國多中心注冊臨床研究由四川大學華西醫院心臟內科陳茂主任牽頭，期待這款國產第一個球擴式瓣膜能夠盡快為中國的患者和醫生提供新的瓣膜解決方案。
-
04 2021-02
2021年1月Mi-thos?經導管二尖瓣置換系統（簡稱“Mi-thos?”）順利通過科技部遺傳辦備案審批（遺傳辦備案號2021BAL0042），宣布正式進入注冊臨床研究階段。Mi-thos?是由上海紐脈醫療和國家生物醫學材料工程技術研究中心張興棟院士團隊、中山醫院王春生主任牽頭，與阜外醫院、西京醫院等醫學團隊聯合技術攻關，獲得國家“十三五”課題和上海市科委科技創新行動計劃支持，累計申請42項國家專利，歷經多年開發成功的一款產品。Mi-thos?有望成為中國首款上市的經導管介入二尖瓣置換的產品，造福廣大的二尖瓣反流（MR）疾病患者。
-
14 2021-01
Jumpcode Genomics Secures $21M in Series B Funding
Jumpcode Genomics – a genome technology company focused on improving the understanding of human disease – today announced it raised $21 million in a Series B round of funding. The round was co-led by Baird Capital and Arboretum Ventures and included existing investor LYZZ Capital. Jumpcode also announced the appointment of Frank Witney to its Board of Directors, further expanding the company’s leadership team. Additionally, the company announced the move of its headquarters into larger office and laboratory space.
-
04 2020-12
Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections
SAN DIEGO, December 3, 2020 – Qpex Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative anti-infective therapies, announced today that it has initiated a Phase 1 clinical study of QPX7728, its novel ultra-broad-spectrum beta-lactamase inhibitor.